p.87 抽出テキスト

192. Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, et al. Identification and assessment of Anderson–Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 2013;6:392–8. https://doi.org/10.1161/CIRCIMAGING.112.000070 193. Holmstrom M, Kivisto S, Helio T, Jurkko R, Kaartinen M, Antila M, et al. Late gadolinium enhanced cardiovascular magnetic resonance of lamin A/C gene mutation related dilated cardiomyopathy. J Cardiovasc Magn Reson 2011;13: 30. https://doi.org/10.1186/1532-429X-13-30 194. Cai S, Haghbayan H, Chan KKW, Deva DP, Jimenez-Juan L, Connelly KA, et al. Tissue mapping by cardiac magnetic resonance imaging for the prognostication of cardiac amyloidosis: a systematic review and meta-analysis. Int J Cardiol 2024;403:131892. https://doi.org/10.1016/j.ijcard.2024.131892 195. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017;19: 1574–85. https://doi.org/10.1002/ejhf.813 196. Graversen CB, Rasmussen LD, Sundboll J, Wurtz M, Kragholm KH, Bottcher M, et al. Cardiac computed tomography for rule-out of ischaemic heart disease in patients with new-onset heart failure. Eur Heart J Cardiovasc Imaging 2025;26:794–801. https://doi.org/10.1093/ehjci/jeaf090 197. Desai D, Maheta DK, Agrawal SP, Abouarab AG, Frishman WH, Aronow WS. Understanding arrhythmia-induced cardiomyopathy: symptoms and treatments. Cardiol Rev 2024. https://doi.org/10.1097/CRD.0000000000000755 198. Shoureshi P, Tan AY, Koneru J, Ellenbogen KA, Kaszala K, Huizar JF. Arrhythmia-induced cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 2024;83:2214–32. https://doi.org/10.1016/j.jacc.2024.03.416 199. Huizar JF, Kaszala K, Tan A, Koneru J, Mankad P, Kron J, et al. Abnormal conduction-induced cardiomyopathy: JACC review topic of the week. J Am Coll Cardiol 2023;81:1192–200. https://doi.org/10.1016/j.jacc.2023.01.040 200. Merkely B, Geller L, Zima E, Osztheimer I, Molnar L, Foldesi C, et al. Baseline clinical characteristics of heart failure patients with reduced ejection fraction enrolled in the BUDAPEST-CRT Upgrade trial. Eur J Heart Fail 2022;24: 1652–61. https://doi.org/10.1002/ejhf.2609 201. Dor O, Haim M, Barrett O, Novack V, Konstantino Y. Incidence and clinical outcomes of pacing induced cardiomyopathy in patients with normal left ventricular systolic function and atrioventricular block. Am J Cardiol 2020; 128:174–80. https://doi.org/10.1016/j.amjcard.2020.05.017 202. Sweeney MO, Hellkamp AS, Ellenbogen KA, Greenspon AJ, Freedman RA, Lee KL, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation 2003;107: 2932–7. https://doi.org/10.1161/01.CIR.0000072769.17295.B1 203. Yu CM, Fang F, Luo XX, Zhang Q, Azlan H, Razali O. Long-term follow-up results of the pacing to avoid cardiac enlargement (PACE) trial. Eur J Heart Fail 2014;16:1016–25. https://doi.org/10.1002/ejhf.157 204. Lu W, Lin J, Dai Y, Chen K, Zhang S. The therapeutic effects of upgrade to cardiac resynchronization therapy in pacing-induced cardiomyopathy or chronic right ventricular pacing patients: a meta-analysis. Heart Fail Rev 2022;27:507–16. https://doi.org/10.1007/s10741-021-10091-z 205. Becker MAJ, Cornel JH, van de Ven PM, van Rossum AC, Allaart CP, Germans T. The prognostic value of late gadolinium-enhanced cardiac magnetic resonance imaging in nonischemic dilated cardiomyopathy: a review and meta-analysis. JACC Cardiovasc Imaging 2018;11:1274–84. https://doi.org/ 10.1016/j.jcmg.2018.03.006 206. Briasoulis A, Mallikethi-Reddy S, Palla M, Alesh I, Afonso L. Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis. Heart 2015;101:1406–11. https://doi.org/10. 1136/heartjnl-2015-307682 207. Duan X, Li J, Zhang Q, Zeng Z, Luo Y, Jiang J, et al. Prognostic value of late gadolinium enhancement in dilated cardiomyopathy patients: a meta-analysis. Clin Radiol 2015;70:999–1008. https://doi.org/10.1016/j. crad.2015.05.007 208. Golukhova EZ, Bulaeva NI, Alexandrova SA, Mrikaev DV, Gromova OI, Ruzina EV, et al. The extent of late gadolinium enhancement predicts mortality, sudden death and major adverse cardiovascular events in patients with nonischaemic cardiomyopathy: a systematic review and meta-analysis. Clin Radiol 2023;78:e342–9. https://doi.org/10.1016/j.crad.2022.12.015 209. Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 2012;5:370–7. https://doi.org/10.1016/j.jcmg. 2011.11.021 210. He D, Ye M, Zhang L, Jiang B. Prognostic significance of late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy. Heart Lung 2018;47:122–6. https://doi.org/10.1016/j.hrtlng. 2017.10.008 211. Helali J, Ramesh K, Brown J, Preciado-Ruiz C, Nguyen T, Silva LT, et al. Late gadolinium enhancement on cardiac MRI: a systematic review and meta-analysis of prognosis across cardiomyopathies. Int J Cardiol 2025; 419:132711. https://doi.org/10.1016/j.ijcard.2024.132711 212. Kamp NJ, Chery G, Kosinski AS, Desai MY, Wazni O, Schmidler GS, et al. Risk stratification using late gadolinium enhancement on cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis. Prog Cardiovasc Dis 2021;66:10–6. https://doi.org/ 10.1016/j.pcad.2020.11.001 213. Kuruvilla S, Adenaw N, Katwal AB, Lipinski MJ, Kramer CM, Salerno M. Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ Cardiovasc Imaging 2014;7:250–8. https://doi. org/10.1161/CIRCIMAGING.113.001144 214. Paterson DI, Wells G, Erthal F, Mielniczuk L, O’Meara E, White J, et al. OUTSMART HF: a randomized controlled trial of routine versus selective cardiac magnetic resonance for patients with nonischemic heart failure (IMAGE-HF 1B). Circulation 2020;141:818–27. https://doi.org/10.1161/ CIRCULATIONAHA.119.043964 215. Weng Z, Yao J, Chan RH, He J, Yang X, Zhou Y, et al. Prognostic value of LGE-CMR in HCM: a meta-analysis. JACC Cardiovasc Imaging 2016;9: 1392–402. https://doi.org/10.1016/j.jcmg.2016.02.031 216. Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076–84. https://doi.org/10.1016/j.jacc.2005.05.073 217. Rauf MU, Hawkins PN, Cappelli F, Perfetto F, Zampieri M, Argiro A, et al. Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis. Eur Heart J 2023;44:2187–98. https://doi.org/10.1093/eurheartj/ehad139 218. Cappelli F, Gallini C, Di Mario C, Costanzo EN, Vaggelli L, Tutino F, et al. Accuracy of 99mTc-hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis. J Nucl Cardiol 2019;26:497–504. https://doi.org/10.1007/s12350-017-0922-z 219. Galat A, Rosso J, Guellich A, Van Der Gucht A, Rappeneau S, Bodez D, et al. Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis. Amyloid 2015;22:210–20. https://doi. org/10.3109/13506129.2015.1072089 220. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016; 133:2404–12. https://doi.org/10.1161/CIRCULATIONAHA.116.021612 221. Longhi S, Guidalotti PL, Quarta CC, Gagliardi C, Milandri A, Lorenzini M, et al. Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. JACC Cardiovasc Imaging 2014;7:531–2. https://doi.org/10.1016/ j.jcmg.2014.03.004 222. Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013;6:195–201. https://doi.org/10.1161/ CIRCIMAGING.112.000132 223. McBenedict B, Hauwanga WN, Amadi ES, Abraham AA, Sivakumar R, Okere MO, et al. Impact of genetic testing on the diagnosis, management, and prognosis of hypertrophic cardiomyopathy: a systematic review. Cureus 2024;16: e70993. https://doi.org/10.7759/cureus.70993 224. Anastasiou V, Papazoglou AS, Gossios T, Zegkos T, Daios S, Moysidis DV, et al. Prognostic implications of genotype findings in non-ischaemic dilated cardiomyopathy: a network meta-analysis. Eur J Heart Fail 2024;26: 2155–68. https://doi.org/10.1002/ejhf.3403 225. Catchpool M, Ramchand J, Martyn M, Hare DL, James PA, Trainer AH, et al. A cost-effectiveness model of genetic testing and periodical clinical screening for the evaluation of families with dilated cardiomyopathy. Genet Med 2019; 21:2815–22. https://doi.org/10.1038/s41436-019-0582-2 226. Christian S, Cirino A, Hansen B, Harris S, Murad AM, Natoli JL, et al. Diagnostic validity and clinical utility of genetic testing for hypertrophic cardiomyopathy: a systematic review and meta-analysis. Open Heart 2022;9: e001815. https://doi.org/10.1136/openhrt-2021-001815 227. Ingles J, McGaughran J, Scuffham PA, Atherton J, Semsarian C. A costeffectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy. Heart 2012;98:625–30. https://doi.org/10. 1136/heartjnl-2011-300368 228. Katzmann JL, Schlattmann P, Rigopoulos AG, Noutsias E, Bigalke B, Pauschinger M, et al. Meta-analysis on the immunohistological detection of inflammatory cardiomyopathy in endomyocardial biopsies. Heart Fail Rev 2020;25:277–94. https://doi.org/10.1007/s10741-019-09835-9 229. Hurrell DG, Nishimura RA, Higano ST, Appleton CP, Danielson GK, Holmes DR Jr, et al. Value of dynamic respiratory changes in left and right ventricular Downloaded from academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag100/8766302 by guest on 31 August 2026